Brighton Jones LLC Buys 579 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Brighton Jones LLC lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.0% during the 4th quarter, HoldingsChannel reports. The firm owned 4,427 shares of the pharmaceutical company’s stock after acquiring an additional 579 shares during the period. Brighton Jones LLC’s holdings in Vertex Pharmaceuticals were worth $1,783,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Northwest Investment Counselors LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $25,000. Highline Wealth Partners LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $27,000. Dunhill Financial LLC boosted its position in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the period. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $33,000. Finally, Truvestments Capital LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $35,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $439.62 on Friday. The firm has a fifty day simple moving average of $435.88 and a two-hundred day simple moving average of $464.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.67 EPS. Analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on VRTX. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $500.00 to $550.00 in a research report on Monday, December 9th. Bank of America cut their target price on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research report on Thursday, December 19th. Stifel Nicolaus boosted their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. Finally, Barclays dropped their price target on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research report on Friday, December 20th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $494.84.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.